Potential risk for new Mpox cases in the United States

Actions requested

• Be aware that mpox (formerly monkeypox) cases continue to be reported, reflecting ongoing community transmission globally, including in King County, Washington.
  
  
• Encourage vaccination for people at greater risk for mpox infection and administer vaccine to those who identify as being high risk
  • Vaccination against mpox remains an important risk-reduction measure
  • People who develop mpox after completing a two-dose JYNNEOS vaccine series may experience less severe symptoms than those who have not.
  • Extensive risk assessment should not be conducted in people who request vaccination to avoid barriers due to stigma experienced by many who could benefit from vaccine.
  • People who previously received only one JYNNEOS vaccine dose should receive a second dose as soon as possible.
  • Mpox vaccine may also be given as post-exposure prophylaxis (PEP) both to people with known or presumed exposure to mpox virus; as PEP, vaccine should be given as soon as possible, ideally within 4 days of exposure but administration 4-14 days after exposure may still provide some protection against mpox.
  • Additional vaccination administration considerations for specific populations are available on the CDC website.
• Refamiliarize yourself with mpox symptoms, specimen collection, laboratory procedures, and treatment options
  • Consider mpox when determining the cause of a diffuse or localized rash, including patients who were previously infected with mpox or vaccinated against mpox.
    • Details noted in patient history, including sexual history may identify possible mpox exposures or epidemiological risk factors.
    • Perform a complete physical examination, including a through skin and mucosal (e.g., oral, genital, anal) examination which may reveal lesions that the patient was unaware of.
  • Patients benefit from individually tailored supportive care and pain management strategies.
  • Continue to consider tecovirimat (also known as TPOXX or ST-246) as first-line therapy for patients with mpox especially among those with severe complications, severe disease or who are at high risk for severe disease.
• Counsel at risk patients about how to reduce the risk of mpox transmission, which often occurs through close, sustained physical contact, almost exclusively associated with sexual contact in the current outbreak.
• Report all cases of mpox immediately to Public Health at 206-296-4774.